Abstract Library

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone

Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Chan B, Wyld D, Burge M, Cuneo R, Macfarlane D,

Keywords: pancreatic, neuroendocrine, tumor, ACTH, everolimus, pasireotide, lutetium,

#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Tan T, Todd J, Al-Nahhas A, Bomanji J,

Keywords: 177Lutetium-DOTATATE therapy, neuroendocrine tumor, paraganglioma, SDHB,